What is the Current Clinical Impact of the CYP2CTG Haplotype?

Clinical Pharmacology & TherapeuticsEarly View Letter to the Editor What is the Current Clinical Impact of the CYP2CTG Haplotype? Magnus Ingelman-Sundberg, Corresponding Author Magnus Ingelman-Sundberg [email protected] orcid.org/0000-0002-7255-9079 Section of Pharmacogenetics, Department of Physiology and Pharmacology, Biomedicum 5B, Karolinska Institutet, Stockholm, Sweden Correspondence: Magnus Ingelman-Sundberg ([email protected])Search for more papers by this authorMarin Jukic, Marin Jukic orcid.org/0000-0002-5296-4245 Section of Pharmacogenetics, Department of Physiology and Pharmacology, Biomedicum 5B, Karolinska Institutet, Stockholm, Sweden Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, SerbiaSearch for more papers by this authorLine Skute Bråten, Line Skute Bråten orcid.org/0000-0001-6887-1986 Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway Department of Health Sciences, OsloMet - Oslo Metropolitan University, Oslo, NorwaySearch for more papers by this authorMarianne Kristiansen Kringen, Marianne Kristiansen Kringen Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway Department of Health Sciences, OsloMet - Oslo Metropolitan University, Oslo, NorwaySearch for more papers by this authorEspen Molden, Espen Molden orcid.org/0000-0001-6190-2751 Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, NorwaySearch for more papers by this author Magnus Ingelman-Sundberg, Corresponding Author Magnus Ingelman-Sundberg [email protected] orcid.org/0000-0002-7255-9079 Section of Pharmacogenetics, Department of Physiology and Pharmacology, Biomedicum 5B, Karolinska Institutet, Stockholm, Sweden Correspondence: Magnus Ingelman-Sundberg ([email protected])Search for more papers by this authorMarin Jukic, Marin Jukic orcid.org/0000-0002-5296-4245 Section of Pharmacogenetics, Department of Physiology and Pharmacology, Biomedicum 5B, Karolinska Institutet, Stockholm, Sweden Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, SerbiaSearch for more papers by this authorLine Skute Bråten, Line Skute Bråten orcid.org/0000-0001-6887-1986 Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway Department of Health Sciences, OsloMet - Oslo Metropolitan University, Oslo, NorwaySearch for more papers by this authorMarianne Kristiansen Kringen, Marianne Kristiansen Kringen Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway Department of Health Sciences, OsloMet - Oslo Metropolitan University, Oslo, NorwaySearch for more papers by this authorEspen Molden, Espen Molden orcid.org/0000-0001-6190-2751 Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, NorwaySearch for more papers by this author First published: 20 November 2023 https://doi.org/10.1002/cpt.3094Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Zubiaur, P. et al. Impact of CYP2C:TG haplotype on CYP2C19 substrates clearance in vivo, protein content, and in vitro activity. Clin. Pharmacol. Ther. (2023). https://doi.org/10.1002/cpt.3012. 2Bråten, L.S. et al. A novel CYP2C-haplotype associated with ultrarapid metabolism of escitalopram. Clin. Pharmacol. Ther. 110, 786–793 (2021). 3Bråten, L.S., Ingelman-Sundberg, M., Jukic, M.M., Molden, E. & Kringen, M.K. Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population. Clin. Transl. Sci. 15, 2135–2145 (2022). 4Ramsjö, M., Aklillu, E., Bohman, L., Ingelman-Sundberg, M., Roh, H.K. & Bertilsson, L. CYP2C19 activity comparison between swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur. J. Clin. Pharmacol. 66, 871–877 (2010). 5El Rouby, N., Lima, J.J. & Johnson, J.A. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin. Drug Metab. Toxicol. 14, 447–460 (2018). Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation